Wraparound IBD care pathway for enhanced patient outcomes

November 29, 2022

BIOHIT is pleased to announce its partnership with Celltrion Healthcare UK Ltd, providing point-of-care assays for the Celltrion Connect Dedicated Homecare Service, which is designed to seamlessly support patients with inflammatory bowel disease (IBD) and their healthcare providers. BIOHIT will be supplying the Preventis SmarTest® Calprotectin Home test – a digital self-test system that combines a faecal calprotectin test with a smartphone app to help patients to monitor their condition in the comfort of their own homes.

The new service has been set up in response to NHS demands and offers a unique 360 degree care package to support IBD patients who have been prescribed Remsima® SC (infliximab). It also provides ongoing education and support from fully dedicated, experienced, specialist nurses – to ensure patients get the most from their medication and achieve the best possible outcomes while on this therapy – and high quality prescription management, dispensing and delivery services.

As part of this care initiative, the SmarTest® rapid lateral flow device will be delivered to patients three times a year for instantaneous snapshots of their disease. A quantitative measurement of faecal calprotectin levels and assessment of disease activity via patient-reported symptoms are recorded using the SmarTest Calprotectin Home app. The results are then automatically sent to the patient’s clinical team within the associated healthcare organisation, so that clinicians can monitor their patients’ conditions remotely with confidence.

Graham Johnson, Managing Director at BIOHIT, commented: “We are delighted to support the Celltrion Connect programme with SmarTest®, an intuitive self-test that is ideally suited to this model of care to truly benefit IBD patient management and outcomes.”

Matt Eddleston, Commercial and Operations Director at Celltrion Healthcare UK Ltd, added: “The partnership with BIOHIT to provide SmarTest is another example of Celltrion Healthcare’s patient centricity, and reflects our desire to truly create value for all the customers we serve.”

For more information about the SmarTest Calprotectin Home test, please visit biohithealthcare.co.uk/biohit-product/smartest-calprotectin-home.


About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health www.biohithealthcare.co.uk

Recent Posts

Unboxing of Peptest

The inside edge on Peptest for the diagnosis of silent reflux

May 20, 2024
National Well-Being

The UK’s Health Landscape And The Endeavor For National Well-Being

May 10, 2024
Endoscopy in a hospital

Tackling the challenge of Helicobacter pylori in record time with the ULTRA-FAST UFT300 Quick Test

February 7, 2024

Exploring the value of biomarkers in gastric cancer screening

October 26, 2023